Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Brain tumor Stories

2014-04-17 08:28:12

VISIUS intraoperative MRI significantly enhances amount of complete resection in brain tumors and leads to better patient outcomes MINNEAPOLIS, April 17, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that a study published this month in the journal Neurosurgery by the neurosurgical team at Cleveland Clinic adds to growing clinical evidence which validates use of high-field intraoperative MRI (iMRI) as an effective tool for...

2014-04-11 08:24:10

CALGARY, April 11, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Alan Melcher, Professor of Clinical Oncology and Biotherapy at the University of Leeds, presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Dr. Melcher's presentation, titled "Clinical Virotherapy and Immune Modulation; Bench to Bedside and Back Again," covered early clinical research showing that...

2014-04-10 08:29:39

Results Continue to Show Safety and Promising Survival; Program to Advance into a Randomized, Controlled Trial SAN DIEGO, April 10, 2014 /PRNewswire/ -- Tocagen Inc. today announced that updated interim clinical data from two ongoing investigational studies of Toca 511 in combination with Toca FC in 68 patients with recurrent high grade glioma were presented at the American Association of Neurological Surgeons (AANS) Annual Meeting in San Francisco. High grade gliomas include...

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-04-09 12:31:14

Three molecularly defined clusters could alter practice; 1 closely resembles deadly glioblastoma Comprehensive genomic analysis of low-grade brain tumors sorts them into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme, the most lethal of brain tumors, researchers reported at the American Association for Cancer Research Annual Meeting 2014. "The immediate clinical implication is that a group of patients with tumors previously...

2014-04-09 08:29:49

SAN FRANCISCO, April 9, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technologies, today announced that preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 Annual Meeting of the American Association of Cancer Research (AACR) being held in San Diego, California. NKTR-102 Presentation Positive preclinical data was presented for NKTR-102...

2014-04-09 08:28:57

Data Supports Development as Non-Invasive Treatment Regimen in a Variety of Cancer Indications LAWRENCEVILLE, N.J., April 9, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that data supporting the development of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, plus high intensity focused ultrasound (HIFU) were presented on April 5, 2014 at the 14th International Symposium on Therapeutic Ultrasound in Las Vegas, Nevada. In a...

2014-04-08 12:30:53

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6d9skh/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/6d9skh/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The delivery of drugs to central nervous system (CNS)...

2014-04-07 16:05:15

Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings identify potential new targets for drug treatments. The new research could help physicians choose targeted agents with a better chance of combating pediatric high-grade astrocytomas, which are extremely difficult to...

2014-04-07 15:55:09

For the first time, researchers have been able to demonstrate that the use of helium ions in radiation therapy could provide accurate treatment to tumors while helping to spare healthy organs. A treatment planning study to be presented at the ESTRO 33 congress today [Sunday] has been able to show that helium may have effects that are superior to radiotherapy using protons, themselves a considerable advance on conventional photon beam radiotherapy. Mr Hermann Fuchs, a PhD student at the...